Abivax Reports H1 2026 Results: €165.9M Net Loss, Cash Runway to Q4 2029, New CMO and CTO
ABVX sits 46% above its 52-week low of $69.81.
Summary
Abivax reported H1 2026 results with a €165.9M net loss and €402.4M in cash, extending runway to Q4 2029. New CMO and CTO appointments support the upcoming obefazimod NDA submission.
Key Events · Earnings and Guidance · ABVX
-
H1 2026 Net Loss of €165.9M
Net loss increased 65% year-over-year from €100.8M to €165.9M, driven by higher R&D expenses (€107.9M, up 38%) and a €43.2M loss on royalty certificate derecognition.
-
Cash Runway Extended to Q4 2029
Cash and short-term investments of €402.4M as of June 30, 2026, combined with €767.1M net proceeds from the July 2026 offering, fund operations into Q4 2029.
-
Royalty Certificate Repurchase Completed
The May 7, 2026 repurchase of all royalty certificates for $90M eliminated a capped €172.1M royalty obligation, resulting in a €43.2M expense and €5.8M deferred tax liability derecognition.
-
New CMO and CTO Appointments
Chris Rabbat succeeds Fabio Cataldi as Chief Medical Officer; Tim Kelly appointed Chief Technical Officer. Both appointments effective immediately, supporting the Q4 2026 NDA submission for obefazimod.
Analysis · ABVX · Life Sciences
The first-half 2026 financials reveal a net loss of €165.9 million and a cash position of €402.4 million as of June 30, 2026. With the €767.1 million in net proceeds from the July 2026 public offering, management projects a cash runway into Q4 2029. Two key executive appointments were also announced — Chris Rabbat as Chief Medical Officer and Tim Kelly as Chief Technical Officer — as the company prepares for the planned NDA submission for obefazimod in Q4 2026. The royalty certificate repurchase completed in May 2026 removed a €172.1 million capped royalty overhang, strengthening the balance sheet ahead of potential commercialization.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABVX was trading at $102.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.1B. The 52-week trading range was $69.81 to $148.83. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.